Last updated on March 2018

Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors


Brief description of study

The purpose of this study is to access the safety and tolerability of the study drug known as SHR-1316 in metastatic/advanced malignancies

Detailed Study Description

This is an open-label, non-randomized, dose escalation/expansion phase I study, SHR-1316 is a humanized IgG4 monoclonal antibody that binds specifically to human PD-L1.The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.

Clinical Study Identifier: NCT03474289

Find a site near you

Start Over